Hinge Health (NYSE:HNGE) Sees Strong Trading Volume Following Earnings Beat

Shares of Hinge Health Inc. (NYSE:HNGE) saw an uptick in trading volume on Tuesday following a stronger than expected earnings report. 1,456,380 shares were traded during trading, an increase of 30% from the previous session’s volume of 1,123,016 shares.The stock last traded at $50.3360 and had previously closed at $48.89.

The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.33. Hinge Health had a negative return on equity of 279.39% and a negative net margin of 78.95%.The firm had revenue of $182.31 million for the quarter. During the same quarter in the previous year, the business posted $1.30 EPS. The business’s quarterly revenue was up 47.2% compared to the same quarter last year.

Key Hinge Health News

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q1 beat and improved outlook: Hinge reported a strong Q1 with revenue up ~47%, EPS above estimates and margin expansion; management raised 2026 guidance, which drove a sharp post?earnings rally. HNGE Stock Up on Q1 Earnings & Revenue Beat
• Positive Sentiment: Raised 2026 outlook and condition expansion: Company lifted its 2026 outlook after strong Q1 execution and announced expansion into additional conditions, supporting revenue diversification and longer-term growth prospects. Hinge Health lifts 2026 outlook after strong Q1
• Positive Sentiment: Product launch & revenue guide: Hinge forecasted $798M–$804M for 2026 and announced the FDA?cleared Enso migraine program launch — a new commercial opportunity that could expand addressable market and revenue per client. Hinge Health forecasts 2026 revenue and launches Enso migraine
• Positive Sentiment: Analyst upward revisions: Multiple brokerages raised price targets and ratings this morning (Wells Fargo, Citizens JMP, Stifel, Needham), signaling stronger sell?side conviction and adding buying interest. Benzinga coverage of upgrades The Fly coverage
• Neutral Sentiment: Earnings call details available: Full Q1 2026 earnings call transcript was published for investors wanting the management commentary on guidance drivers, sales pipeline and margin cadence. Q1 2026 Earnings Call Transcript
• Negative Sentiment: Profitability still a watch item: despite the beat, the company remains unprofitable on a net?margin and ROE basis; investors should watch margin trajectory and cash flow conversion as growth scales. Background data

Analysts Set New Price Targets

A number of brokerages have recently weighed in on HNGE. Stifel Nicolaus lifted their price objective on Hinge Health from $59.00 to $67.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup reaffirmed an “outperform” rating on shares of Hinge Health in a research note on Wednesday. Freedom Capital raised Hinge Health to a “strong-buy” rating in a research note on Thursday, January 22nd. Royal Bank Of Canada lifted their price objective on Hinge Health from $55.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, KeyCorp set a $55.00 target price on Hinge Health in a research note on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Hinge Health presently has an average rating of “Moderate Buy” and an average target price of $67.40.

Insiders Place Their Bets

In other Hinge Health news, CFO James Budge sold 11,006 shares of Hinge Health stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $42.26, for a total transaction of $465,113.56. Following the completion of the sale, the chief financial officer directly owned 401,427 shares of the company’s stock, valued at $16,964,305.02. The trade was a 2.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, President James Pursley sold 15,000 shares of Hinge Health stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $42.26, for a total value of $633,900.00. Following the sale, the president directly owned 732,104 shares of the company’s stock, valued at $30,938,715.04. This trade represents a 2.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 442,670 shares of company stock valued at $18,786,901 over the last quarter. Corporate insiders own 18.92% of the company’s stock.

Institutional Trading of Hinge Health

A number of institutional investors have recently bought and sold shares of HNGE. Marshall Wace LLP purchased a new stake in Hinge Health during the 2nd quarter worth about $367,000. Sei Investments Co. purchased a new stake in Hinge Health during the 2nd quarter worth about $869,000. Squarepoint Ops LLC purchased a new stake in Hinge Health during the 2nd quarter worth about $19,706,000. Raymond James Financial Inc. purchased a new stake in Hinge Health during the 2nd quarter worth about $3,258,000. Finally, Sandia Investment Management LP purchased a new stake in shares of Hinge Health in the 2nd quarter valued at about $657,000.

Hinge Health Trading Up 0.1%

The firm has a market capitalization of $4.33 billion and a PE ratio of -4.45. The company has a fifty day moving average price of $42.81 and a two-hundred day moving average price of $44.00.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.